Northland Securities reaffirmed their buy rating on shares of Opiant Pharmaceuticals (NASDAQ:OPNT) in a research note published on Thursday, AnalystRatings.com reports. Northland Securities currently has a $42.00 target price on the technology company’s stock.
Separately, TheStreet upgraded Opiant Pharmaceuticals from a d rating to a c- rating in a research report on Friday, August 30th.
OPNT traded up $0.38 during trading hours on Thursday, hitting $15.80. 6,400 shares of the stock were exchanged, compared to its average volume of 20,137. The stock has a 50-day simple moving average of $15.06 and a 200-day simple moving average of $13.47. Opiant Pharmaceuticals has a 12 month low of $9.98 and a 12 month high of $17.02. The stock has a market cap of $61.02 million, a price-to-earnings ratio of -2.23 and a beta of 0.31.
Opiant Pharmaceuticals (NASDAQ:OPNT) last announced its earnings results on Thursday, August 8th. The technology company reported $0.31 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.55) by $0.86. Opiant Pharmaceuticals had a negative return on equity of 12.74% and a negative net margin of 11.78%. The business had revenue of $6.78 million during the quarter, compared to analysts’ expectations of $3.91 million. As a group, equities research analysts anticipate that Opiant Pharmaceuticals will post 1.05 earnings per share for the current fiscal year.
In other Opiant Pharmaceuticals news, Director Michael Sinclair sold 60,000 shares of the firm’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $12.52, for a total transaction of $751,200.00. Also, insider Phil Skolnick sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $15.80, for a total value of $158,000.00. Insiders sold a total of 90,000 shares of company stock valued at $1,197,500 in the last quarter. 30.88% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Advisor Group Inc. raised its stake in shares of Opiant Pharmaceuticals by 24.3% during the 2nd quarter. Advisor Group Inc. now owns 4,600 shares of the technology company’s stock worth $61,000 after purchasing an additional 900 shares in the last quarter. BlackRock Inc. raised its stake in shares of Opiant Pharmaceuticals by 93.5% during the 2nd quarter. BlackRock Inc. now owns 20,792 shares of the technology company’s stock worth $276,000 after purchasing an additional 10,045 shares in the last quarter. Morgan Stanley raised its stake in shares of Opiant Pharmaceuticals by 1,000.3% during the 2nd quarter. Morgan Stanley now owns 22,414 shares of the technology company’s stock worth $297,000 after purchasing an additional 20,377 shares in the last quarter. Wedge Capital Management L L P NC purchased a new stake in shares of Opiant Pharmaceuticals during the 3rd quarter worth about $363,000. Finally, Stonepine Capital Management LLC raised its stake in shares of Opiant Pharmaceuticals by 7.0% during the 2nd quarter. Stonepine Capital Management LLC now owns 315,468 shares of the technology company’s stock worth $4,180,000 after purchasing an additional 20,574 shares in the last quarter. Hedge funds and other institutional investors own 20.82% of the company’s stock.
Opiant Pharmaceuticals Company Profile
Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.
Featured Story: What is Cost of Debt?
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.